Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Multi-arm clinical trials of new agents: some design considerationsBoris Freidlin, Edward L Korn, Robert Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2007
Randomized clinical trial design for assessing noninferiority when superiority is expectedBoris Freidlin, Edward L Korn, Stephen L George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007Edward L Korn, Boris Freidlin, Margaret Mooney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Design issues in randomized phase II/III trialsEdward L Korn, Boris Freidlin, Jeffrey S Abrams, et al.
JNCI Cancer Spectrum|November 24, 2023
The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experienceJared C Foster, Edward L Korn, Boris Freidlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Multinomial phase II trial designsBoris Freidlin, Janet Dancey, Edward L Korn, et al.
Journal of the National Cancer Institute|January 25, 2026
Changing standard of care during a randomized trial: examples, considerations and guidelinesBoris Freidlin, Malcolm A Smith, Carmen J Allegra, et al.
Journal of the National Cancer Institute|September 24, 2019
Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017Jared C Foster, Boris Freidlin, Charles A Kunos, et al.
Biometrics|January 8, 2011
An audit strategy for progression-free survivalLori E Dodd, Edward L Korn, Boris Freidlin, et al.
Clinical Trials (London, England)|January 3, 2026
A note on rank-preserving structural failure time models to account for crossoverPedro A Torres-Saavedra, Boris Freidlin, Jong-Hyeon Jeong, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Multi-arm clinical trials of new agents: some design considerationsBoris Freidlin, Edward L Korn, Robert Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2007
Randomized clinical trial design for assessing noninferiority when superiority is expectedBoris Freidlin, Edward L Korn, Stephen L George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007Edward L Korn, Boris Freidlin, Margaret Mooney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Design issues in randomized phase II/III trialsEdward L Korn, Boris Freidlin, Jeffrey S Abrams, et al.
JNCI Cancer Spectrum|November 24, 2023
The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experienceJared C Foster, Edward L Korn, Boris Freidlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Multinomial phase II trial designsBoris Freidlin, Janet Dancey, Edward L Korn, et al.
Journal of the National Cancer Institute|January 25, 2026
Changing standard of care during a randomized trial: examples, considerations and guidelinesBoris Freidlin, Malcolm A Smith, Carmen J Allegra, et al.
Journal of the National Cancer Institute|September 24, 2019
Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017Jared C Foster, Boris Freidlin, Charles A Kunos, et al.
Biometrics|January 8, 2011
An audit strategy for progression-free survivalLori E Dodd, Edward L Korn, Boris Freidlin, et al.
Clinical Trials (London, England)|January 3, 2026
A note on rank-preserving structural failure time models to account for crossoverPedro A Torres-Saavedra, Boris Freidlin, Jong-Hyeon Jeong, et al.
Pageof 12